title: Successful initial treatment with weekly etoposide, epirubicin, cisplatin, 5-fluorouracil and leucovorin chemotherapy in advanced gastric cancer patients with disseminated intravascular coagulation.
abstract: BACKGROUND
  Acute disseminated intravascular coagulation (DIC) is a rare but severe complication of gastric adenocarcinoma. Conventional treatments, such as fresh frozen plasma, platelet replacement and heparin injections, are disappointing. The only way to correct this fatal condition is to control the underlying cancer promptly by effective chemotherapy. Here the successful initial control of acute DIC in gastric cancer patients with weekly EEPFL chemotherapy is reported.
  
  
  METHODS
  Advanced gastric cancer patients complicated with acute DIC were eligible. Patients were treated with weekly EEPFL therapy (etoposide 40, epirubicin 10, cisplatin 25, 5-fluorouracil 2200 and leucovorin 120 mg/m2 ). Response, survival and toxicity were evaluated.
  
  
  RESULTS
  From April 1997 to April 1999, six patients were included in this study. All patients received EEPFL chemotherapy. Clinical and laboratory evidence of acute DIC stabilized quickly after starting chemotherapy. Four patients showed a partial response, one stable disease and one progressive disease. The toxicity was mild and well tolerated. Median survival was 28 weeks (12, 14, 26, 30, 30 and 32 weeks). All patients suffered from a relapse of DIC after initial successful control and died within 30 days of clinical and laboratory evidence of acute DIC relapse.
  
  
  CONCLUSIONS
  EEPFL therapy is an effective chemotherapy regimen for patients with advanced gastric cancer associated with acute DIC. The prognosis is poor if the DIC relapses after the initial successful control.
authors.affiliation: Division of Gastroenterology, Veterans General Hospital, Taipei, Taiwan. chaoy@vghtpe.gov.tw
authors.forename: Y
authors.initials: Y
authors.lastname: Chao
authors.forename: H C
authors.initials: HC
authors.lastname: Teng
authors.forename: H C
authors.initials: HC
authors.lastname: Hung
authors.forename: K L
authors.initials: KL
authors.lastname: King
authors.forename: C P
authors.initials: CP
authors.lastname: Li
authors.forename: K H
authors.initials: KH
authors.lastname: Chi
authors.forename: S H
authors.initials: SH
authors.lastname: Yen
authors.forename: F Y
authors.initials: FY
authors.lastname: Chang
mesh_terms: D000208:Acute Disease; D000230:Adenocarcinoma / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D004211:Disseminated Intravascular Coagulation / Q000150:complications*; D015251:Epirubicin / Q000008:administration & dosage / Q000009:adverse effects; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D013274:Stomach Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D015996:Survival Rate
chemical_list: D015251:Epirubicin; D005047:Etoposide; D002945:Cisplatin; D002955:Leucovorin; D005472:Fluorouracil